Non-small Cell Lung CancerEsophageal CancerBreast Cancer Female
Investigational drug(s) / intervention(s)
Imaging and biomarkers
Imaging and biomarkers: MR imaging of the heart, ECG and TTE measurements, blood sample
Study summary
Late side effects in radio(chemo)therapy \[R(CH)T\] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic region, risk stratification models for these toxicities are lacking. In this study, liquid, functional and imaging biomarkers are being investigated for their use in prediction of cardiac toxicity following R(CH)T for patients with thoracic malignancies.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients 18 years old or older
* Patient's consent and written consent is available
* Patients with the non-small cell lung cancer or esophageal cancer or breast cancer who have an indication for intended curative radio(chemo)therapy (in the case of breast cancer inclusion of female patients only)
Exclusion Criteria:
* Patients who are not capable of giving consent
* Pregnant women
* Patients with contraindications for MRI examinations (pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, permanent make-up, metal splinters or osseosynthetic implants)
* Patients with insufficient kidney function (glomerular filtration rate (GFR) of less than 30 ml/min)
* Patients with the aforementioned tumour entities for whom a palliative indication exists
Primary outcome measure(s)
Cumulative cardio-toxicity after 1 or 5 years — 12 or 60 months after end of treatment Cumulative grade ≥ 2 cardio-toxicity (Common Terminology Criteria for Adverse Events \[CTCAE\] v 5.0) 1 years after R(CH)T in patients with non-small cell lung or esophageal cancer or 5 years after R(CH)T in patients with breast cancer
Trial sites (1)
Facility
City
Region
Status
University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology
Dresden
Germany
More Technische Universität Dresden trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.